Elan in deal with Abbott, AstraZeneca

Abbott Pharmaceutical and AstraZeneca have been granted the US rights to use Elan’s NanoCrystal Technology to develop fixed-dose combination products.

Under the terms of the agreement, Elan will receive payments upon the achievement of development, clinical, and regulatory milestones for such new products.